CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$5.76
-0.29 (-4.71%)
▼
5d:
-5.26%
30d:
+0.61%
90d:
-2.62%
HOLD
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 22, 2026
18d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CSBR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CSBR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $5.76, which is considered slightly low relative to its 30-day fair value range of $5.73 to $6.44. The stock's valuation (Forward PE: 57.6) is in line with its historical norms (57.3). At these levels, the market is pricing in 0.2% annual earnings growth.
Technical Outlook: Technically, CSBR is in a downtrend. The price is currently testing key support at $5.60. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+108.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CSBR is in a downtrend. The price is currently testing key support at $5.60. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+108.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.73 -
$6.44
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 108.3% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 0.2% growth with -2.8% revenue growth
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.73 -
$6.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.60
Resistance Level
$7.00
Current Trend
Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
57.60
Wall Street Target
$12.00
(+108.3%)
Revenue Growth (YoY)
-2.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-4.0%
Valuation Premium vs History
+0.2% premium
PE vs Historical
57.6 vs 57.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$5.77
(+0%)
2-Year Target
$5.78
(+0%)
3-Year Target
$5.79
(+1%)
3-Yr Target (if PE normalizes)
(PE: 58→57)
PE COMPRESSION
$5.76
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 57.6, Growth: -16.7%)
$4.20
(+-27%)
Base:
(SPY PE: 21.8, Growth: -16.7%)
$1.59
(-72%)
Bear:
(PE: 18.5, Growth: -16.7%)
$1.35
(-77%)
Share & Embed Analysis
Last updated: July 02, 2026 10:40 PM ET
Data refreshes hourly during market hours. Next update: 11:40 PM
Data refreshes hourly during market hours. Next update: 11:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
